Fig. 3

A Effect of Muse cells in damaged liver. Functional improvement shown in Muse cells by a decrease in bilirubin production, increase in albumin levels, and decrease in fibrotic tissues. B Effect of Muse cells in damaged kidney: (b₁) detection of GFP(+) Muse cells distributed in different tissues after 7 weeks of injection in FSGS-SCID mice; (b₂, b₃) Muse cells show significant decrease in glomerular sclerosis as well as fibrotic areas. C Effect of Muse cells in damaged neural tissue: (c₁) ipsilateral sensory cortex analysis in cerebral stroke-SCID mice after 84 days of Muse, non-Muse, and vehicle treatment; somatosensory evoked potentials show no effect in latency (c₂) and significant increase in amplitude (c₃) between Muse cells and vehicle controls; (c₄) integration of GFP(+) Muse cells into neural tissue at days 3 and 7 display neurite-like cell formation. D Effect of Muse cells in diabetic skin ulcers: (d₁) Muse-rich fraction shows significant reduction in percent wounded area in comparison with Muse-poor fraction at 14 days post implantation; (d₂) Muse-rich fraction expresses PECAM-1 and isolectin (markers of dermis and vascular endothelial cells) in upper dermis at 14 days post implantation; (d₃) Muse cells show negative expression of PECAM-1 and isolectin in middle and lower dermis 14 days post implantation. Muse multilineage differentiating stress enduring, ns not significant (A Reproduced with permission from Figure 4 in Iseki et al. [26]) (b₁ Reproduced with permission from Figure 2 in Uchida et al. [46], License Number 4141730401653) (b₂, b₃ Reproduced with permission from Figure 6 in Uchida et al. [46], License Number 4141730401653) (c₁–c₃ Reproduced from Figure 6 in Uchida et al. [23] under CC-BY license) (c₄ Reproduced from Figure 7 in Uchida et al. [23] under CC-BY license) (d₁ Reproduced with permission from Figure 5 in Kinoshita et al. [21], License Number 4136900281603) (d₂, d₃ Reproduced with permission from Figure 7 in Kinoshita et al. [21], License Number 4136900281603)